Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Communications
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER has 3 pending office actions within the Communications technology area. These actions are distributed across 2 distinct art units, indicating a focused but varied technical scope. The portfolio involves 3 distinct examiners, which means that every pending matter is being reviewed by a different person at the patent office.
LEWOCZKO, EVAN MICHAEL is the busiest examiner for the center, with 1 pending office action. This single action is one of the 3 total pending actions currently in progress. The use of 3 distinct examiners for 3 actions shows a lack of examiner concentration, even though the work is focused within 2 art units in the communications field. For practitioners, this decentralized structure means that there is no single examiner style to master. Instead, the 3 pending office actions require 3 individual strategies tailored to the specific examiners involved. The distribution of 3 actions across 2 art units suggests that while the examiners are different, the technical subject matter is relatively concentrated. Successfully managing these 3 pending matters will require navigating the individual styles of the 3 distinct examiners within the Communications sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEWOCZKO, EVAN MICHAEL | 1 | — | — |
| GEBRESLASSIE, WINTA | 1 | 77.1% | +23.6% |
| DUTT, ADITI | 1 | 47.0% | +48.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18727234 | SYSTEMS AND METHODS OF GENERATING LIPID, PROTEIN, AND/OR PROTEIN SHELLED BUBBLES | LEWOCZKO, EVAN MICHAEL | — |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651752 | RISK PREDICTION OF HEART FAILURE | GEBRESLASSIE, WINTA | — |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | — |
| Art Unit | Apps |
|---|---|
| 2677 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18727234 | SYSTEMS AND METHODS OF GENERATING LIPID, PROTEIN, AND/OR PROTEIN SHELLED BUBBLES | LEWOCZKO, EVAN MICHAEL | — | §102§103§112 | Non-Final OA | — | Pending | Jul 08, 2024 |
| 18651752 | RISK PREDICTION OF HEART FAILURE | GEBRESLASSIE, WINTA | 2677 | §103 | Final Rejection | — | Pending | May 01, 2024 |
| 17790480 | Biomarker and Druggable Target of Neurodegeneration | DUTT, ADITI | 1675 | §103§112 | Final Rejection | — | Pending | Jun 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial